Yusuke Okuda, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intestinal Obstruction | 4 | 2023 | 424 | 2.180 |
Why?
|
| Colorectal Neoplasms | 5 | 2023 | 6773 | 0.770 |
Why?
|
| Stomach Neoplasms | 5 | 2020 | 1332 | 0.750 |
Why?
|
| Ribonuclease III | 1 | 2020 | 275 | 0.650 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 375 | 0.610 |
Why?
|
| Anal Canal | 1 | 2019 | 376 | 0.570 |
Why?
|
| MicroRNAs | 3 | 2021 | 3750 | 0.550 |
Why?
|
| Colorectal Surgery | 1 | 2018 | 128 | 0.550 |
Why?
|
| Exosomes | 1 | 2020 | 419 | 0.540 |
Why?
|
| Laparoscopy | 3 | 2021 | 2148 | 0.440 |
Why?
|
| Duodenal Neoplasms | 2 | 2021 | 106 | 0.390 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1585 | 0.380 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 2542 | 0.380 |
Why?
|
| Adenocarcinoma | 3 | 2021 | 6363 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 9239 | 0.240 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2021 | 1131 | 0.190 |
Why?
|
| Chemokine CXCL2 | 1 | 2020 | 116 | 0.180 |
Why?
|
| Peptic Ulcer | 1 | 2021 | 223 | 0.170 |
Why?
|
| Omentum | 1 | 2020 | 170 | 0.170 |
Why?
|
| Lipoma | 1 | 2021 | 334 | 0.170 |
Why?
|
| Case-Control Studies | 4 | 2023 | 21733 | 0.140 |
Why?
|
| Coculture Techniques | 1 | 2020 | 1342 | 0.140 |
Why?
|
| Diverticulum, Colon | 1 | 2015 | 33 | 0.140 |
Why?
|
| Helicobacter pylori | 1 | 2019 | 384 | 0.140 |
Why?
|
| Colectomy | 1 | 2019 | 680 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2021 | 1092 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 665 | 0.120 |
Why?
|
| Colonic Diseases | 1 | 2015 | 202 | 0.120 |
Why?
|
| Duodenum | 3 | 2021 | 484 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 1637 | 0.110 |
Why?
|
| Adenoma | 1 | 2021 | 2173 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 1968 | 0.100 |
Why?
|
| Stents | 1 | 2023 | 3280 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 1888 | 0.090 |
Why?
|
| Aged | 8 | 2021 | 163178 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 3510 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2023 | 77410 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 2638 | 0.080 |
Why?
|
| Middle Aged | 8 | 2021 | 213241 | 0.080 |
Why?
|
| Humans | 19 | 2023 | 743811 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 57744 | 0.080 |
Why?
|
| Colonoscopy | 1 | 2015 | 1367 | 0.080 |
Why?
|
| Acute Disease | 1 | 2018 | 7150 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 16674 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 11036 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3089 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2023 | 63042 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8637 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5264 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2018 | 10251 | 0.060 |
Why?
|
| Adipocytes | 2 | 2023 | 1182 | 0.060 |
Why?
|
| Cytokines | 1 | 2019 | 7324 | 0.060 |
Why?
|
| Male | 8 | 2021 | 349776 | 0.060 |
Why?
|
| Female | 9 | 2021 | 380020 | 0.060 |
Why?
|
| Survival Rate | 1 | 2018 | 12786 | 0.060 |
Why?
|
| Electrosurgery | 1 | 2023 | 58 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8430 | 0.060 |
Why?
|
| Electrocoagulation | 1 | 2023 | 158 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 13691 | 0.050 |
Why?
|
| Osteopontin | 1 | 2023 | 294 | 0.050 |
Why?
|
| Inflammation | 1 | 2019 | 10629 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2020 | 537 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11524 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2021 | 1185 | 0.040 |
Why?
|
| Prognosis | 1 | 2018 | 29052 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 3249 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 1654 | 0.040 |
Why?
|
| Stomach | 1 | 2021 | 697 | 0.040 |
Why?
|
| Helicobacter Infections | 1 | 2019 | 388 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2020 | 2718 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 56392 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1691 | 0.030 |
Why?
|
| Hemostasis | 1 | 2015 | 458 | 0.030 |
Why?
|
| Adult | 3 | 2021 | 213889 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2019 | 1705 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 2504 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2020 | 4221 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2023 | 3482 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2020 | 8436 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2023 | 10477 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2023 | 7270 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14714 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 81154 | 0.020 |
Why?
|
| Aspirin | 1 | 2015 | 3283 | 0.010 |
Why?
|
| Contrast Media | 1 | 2015 | 5301 | 0.010 |
Why?
|
| Risk Factors | 2 | 2021 | 72252 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 12744 | 0.010 |
Why?
|
| Animals | 2 | 2023 | 168660 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23327 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2023 | 53250 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 29777 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2020 | 23398 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 40545 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20121 | 0.010 |
Why?
|